ESTRO 2025 - Abstract Book

S752

Clinical - CNS

ESTRO 2025

Objective response rate (understood as partial or stable-disease monitoring by MRI) was 97%. Five and ten-year overall survival was 96.5 and 91%, with 98% and 94% progression-free survival at five and ten-year respectively.

Post-treatment hormonal deficiencies: 27% (GH axis), 27% (TSH axis), 13% (adrenal axis), 40% and 8.9 % (sexual hormones in men and women respectively). Panhypopituitarism (understood as hormone deficiency of the four axes): 2%. One patient experienced new visual alterations, and one had pituitary apoplexy post-radiotherapy. No second malignancies were reported. Conclusion: Radiotherapy is safe and effective for pituitary adenomas, but long-term follow-up is essential for managing hormonal deficits.